SuperGen Plans Dacogen Bone Marrow Disorder NDA; Pharmion Files Vidaza
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The "state of the art" clinical trials in SuperGen’s Dacogen NDA for myelodysplastic syndrome may give the product an edge over Pharmion’s pending MDS agent, Vidaza, SuperGen claims.